HTLV-1: the silent impact revealed

The seminal publication in The Lancet Infectious Diseases by Gill Schierhout and colleagues looking at disease outcomes for which HTLV-1 is not a necessary diagnostic criterion shows that morbidity and mortality are clearly associated with HTLV-1 infection.5 The authors report a 57% increased risk o...

Full description

Saved in:
Bibliographic Details
Published inThe Lancet infectious diseases Vol. 20; no. 1; pp. 12 - 14
Main Authors Cook, Lucy B M, Taylor, Graham P
Format Journal Article
LanguageEnglish
Published United States Elsevier Ltd 01.01.2020
Elsevier Limited
Subjects
Breastfeeding & lactation
Central nervous system diseases
Cost benefit analysis
Diagnostic systems
Health care policy
Infections
Infectious diseases
Leukemia
Lymphocytes T
Lymphoma
Morbidity
Pathogenesis
Public health
Spastic paraparesis
Spinal cord
Tropical spastic paraparesis
Tuberculosis
North America
Africa
Online AccessGet full text

Cover

More Information
Summary:The seminal publication in The Lancet Infectious Diseases by Gill Schierhout and colleagues looking at disease outcomes for which HTLV-1 is not a necessary diagnostic criterion shows that morbidity and mortality are clearly associated with HTLV-1 infection.5 The authors report a 57% increased risk of premature death that is independent of adult T-cell leukaemia-lymphoma (ATL) and HTLV-1-associated myelopathy or tropical spastic paraparesis (HAM/TSP), the two well known HTLV-1-associated diseases that require HTLV-1 as a prerequisite to their diagnosis. [...]a change in perception of the public health importance of HTLV-1 including cost–benefit analyses, by region, of screening programmes. [...]better funding to address the huge gaps in pathogenesis and treatment.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Commentary-1
ISSN:1473-3099
1474-4457
DOI:10.1016/S1473-3099(19)30432-3